Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricolinostat + pomalidomide + low-dose dexamethasone in relapsed/refractory multiple myeloma
2014-002338-29Phase 2Completed
- Sponsor
- Acetylon Pharmaceuticals, Inc.
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ricolinostat, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Acetylon Pharmaceuticals, Inc. Primary endpoints: Maximum tolerated dose, Safety and 1 more. Started May 2015; status: completed.
02
Drugs
ricolinostatpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-002338-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002338-29.